Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer

Invest New Drugs. 2002 May;20(2):195-200. doi: 10.1023/a:1015670126203.

Abstract

Peroxisome proliferator activated receptor-gamma (PPARgamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPARgamma is expressed at high levels in adipose tissue and plays a central role in adipocyte differentiation. Recent studies have implicated PPARgamma in the pathogenesis of several human malignancies. Here we review the evidence that PPARgamma contributes to prostate carcinogenesis and the potential for PPARgamma as a novel therapeutic target for prostate cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Chromans / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Male
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / etiology
  • Prostatic Neoplasms* / metabolism
  • Receptors, Cytoplasmic and Nuclear* / genetics
  • Receptors, Cytoplasmic and Nuclear* / physiology
  • Thiazoles / therapeutic use*
  • Thiazolidinediones*
  • Transcription Factors* / adverse effects
  • Transcription Factors* / genetics
  • Transcription Factors* / physiology
  • Troglitazone

Substances

  • Antineoplastic Agents
  • Chromans
  • Receptors, Cytoplasmic and Nuclear
  • Thiazoles
  • Thiazolidinediones
  • Transcription Factors
  • Troglitazone